CLINICAL TRIALS PROFILE FOR NADOLOL

All Clinical Trials for nadolol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00390546 ↗	Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia	Completed	The Hospital for Sick Children	Phase 3	2006-10-01	This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
NCT00390546 ↗	Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia	Completed	University of Utah	Phase 3	2006-10-01	This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
NCT00390546 ↗	Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia	Completed	University of British Columbia	Phase 3	2006-10-01	This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.

Clinical Trial Conditions for nadolol

Condition Name

Condition Name for nadolol
Intervention	Trials
Variceal Bleeding	2
Gastrointestinal Hemorrhage	2
Healthy	2
Cardiac Failure	2

Condition MeSH

Condition MeSH for nadolol
Intervention	Trials
Hypertension	5
Hemorrhage	4
Liver Cirrhosis	3
Hypertension, Portal	3

Clinical Trial Locations for nadolol

Trials by Country

Trials by Country for nadolol
Location	Trials
United States	33
Canada	6
Spain	2
Puerto Rico	1
Taiwan	1

Trials by US State

Trials by US State for nadolol
Location	Trials
Ohio	4
New York	3
Missouri	3
California	2
Texas	2

Clinical Trial Progress for nadolol

Clinical Trial Phase

Clinical Trial Phase for nadolol
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	3
Phase 2	4

Clinical Trial Status

Clinical Trial Status for nadolol
Clinical Trial Phase	Trials
Completed	14
Unknown status	4
Enrolling by invitation	2

Clinical Trial Sponsors for nadolol

Sponsor Name

Sponsor Name for nadolol
Sponsor	Trials
Invion, Inc.	3
The Hospital for Sick Children	3
National Science Council, Taiwan	3

Sponsor Type

Sponsor Type for nadolol
Sponsor	Trials
Other	23
Industry	11
U.S. Fed	2